Advanced Cardiovascular Systems (GDT)

Catheters for coronary angioplasty. ACS was acquired by Eli Lilly and later spun out to the public as Guidant Corp. Guidant is a leader in the design and development of cardiovascular medical products.

USVP Contact:

Bill Bowes

print version

Aerogen

Novel pharmaceutical products based on proprietary aerosolization technology for treatment of respiratory disorders in the critical care setting and inhalation systems for pulmonary delivery of insulin. Aerogen completed an IPO in November 2000 and was acquired by Nektar in October 2005.

USVP Contact:

Phil Young

print version

Altus Pharmaceuticals (ALTU)

Altus Pharmaceuticals develops and commercializes novel protein therapeutics for patients with chronic gastrointestinal and metabolic diseases.

USVP Contact:

Jon Root

print version

Applied Biosystems (ABI)

Applied Biosystems (acquired by PerkinElmer), a business unit of Applera Corporation, serves the life sciences industry and research community by developing and marketing instrumant-based systems, consumables, software and services.

USVP Contact:

Bill Bowes

print version

Ascenta Therapeutics

Novel small molecules for the treatment of cancer.

USVP Contact:

USVP

print version

AtriCure

Manufactures and distributes ablative systems that provide surgeons with alternatives for treatment of patients diagnosed with atrial fibrillation.

USVP Contact:

Alan Kaganov

print version

Bayhill Therapeutics

Biopharmaceutical company developing therapies for the treatment of autoimmune diseases, including multiple sclerosis and Type I diabetes, based on technologies that originated in Prof. Lawrence Steiman, M.D.'s laboratory at Stanford.

USVP Contact:

Phil Young and Jon Root

print version

CardioKinetix

Medical implants that treat ventricular wall motion abnormalities which occur after an AMI and can progress to end-stage heart failure.

USVP Contact:

Alan Kaganov

print version

CryoVascular Systems

CryoVascular Systems (acquired by Boston Scientific) developed and commercialized a novel therapy for the treatment for peripheral vascular and cardiovascular disease.

USVP Contact:

Jon Root

print version

Ensure Medical

Ensure Medical (acquired by Johnson & Johnson) developed a proprietary vascular access closure device.

USVP Contact:

Jon Root

print version

Genta (GNTA)

Develops biopharmaceuticals for anti-viral and anti-cancer treatments.

USVP Contact:

Bill Bowes

print version

Glycomed

Glycomed (acquired by Ligand) develops pharmaceuticals based on complex carbohydrate bioactivity.

USVP Contact:

Bill Bowes

print version

GN ReSound

Advanced technology hearing aid systems.

USVP Contact:

Phil Schlein

print version

Ilypsa

Ilypsa (acquired by Amgen) is a therapeutics platform spinout of Symx that develops novel polymer-based, orally bioavailable therapies to treat renal failure and metabolic disorders.

USVP Contact:

Jon Root and Casper de Clercq

print version

Integrated Vascular Systems

Integrated Vascular Systems (acquired by Abbott Laboratories) develops next-generation proprietary vascular closure devices for use in intravascular diagnostic and therapeutic applications.

USVP Contact:

Jon Root

print version

Matritech (MZT)

Leading developer of proteomics-based diagnostic products for the early detection of cancer. Using its patented proteomics technology, Matritech has identified proteins correlated with bladder, cervical, breast, prostate and colon cancers.

USVP Contact:

Phil Young

print version

MicroHeart

Develops drug delivery systems for angiogensis.

USVP Contact:

Phil Young

print version

MicroVention

MicroVention (acquired by Terumo Medical) is a rapidly growing medical device company pioneering the development of catheter-based technologies for the endovascular treatment of peripheral and cerebral vascular diseases.

USVP Contact:

Jon Root

print version

OncoMed Pharmaceuticals

Developing innovative pharmaceuticals for solid tumors, based on the recent identification of cancer stem cells.

USVP Contact:

Jon Root

print version

Proteolix

Biopharmaceutical company committed to the discovery, clinical development and marketing of drugs that inhibit the proteasome-mediated protein degradation pathway in cells for the treatment of cancer.

USVP Contact:

Jon Root

print version

Raven Biotechnologies

Focused on the development of monoclonal antibodies therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas of the GI tract and is currently in human clinical trials.

USVP Contact:

Jon Root

print version

Sanarus Medical

Provides minimally-invasive solutions for the screening, diagnosis and treatment of breast disease, including breast cancers and non-malignant growths.

USVP Contact:

Alan Kaganov

print version

SanDisk

The world's largest supplier of flash memory data storage cards and related end-user products for digital film, MP3 music players, USB devices and other consumer applications.

USVP Contact:

Irwin Federman

print version

Solexa

Solexa, Inc. (formerly Lynx Therapeutics) is developing and preparing to commercialize a new platform for genetic analysis based on Sequencing-by-Synthesis (SBS) and Cluster molecular arrays.

USVP Contact:

Bill Bowes

print version

Spectranetics

Develops, manufactures and markets "cool" ultraviolet excimer laser technology for multiple cardiovascular procedures to physicians and hospitals worldwide.

USVP Contact:

Phil Young

print version

St. Francis Medical Technologies

St. Francis Medical Technologies (Acquired by Kyphon) develops new, minimally invasive technologies and procedures for the treatment of leg and back pain.

USVP Contact:

Alan Kaganov

print version

Ventritex

Ventritex (acquired by St. Jude Medical) manufactures mechanical and tissue heart valves, pacemakers, implantable cardioverter defibrillators and electrophysiology catheters.

USVP Contact:

Bill Bowes

print version

Vical (VICL)

Researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases.

USVP Contact:

Phil Young

print version

Xoma

Develops biopharmaceuticals that target cancer, immunological disorders and infectious diseases. Its product, RAPTIVA, is the first FDA-approved biologic therapy designed to provide continuous control of chronic moderate-to-severe plaque psoriasis.

USVP Contact:

Bill Bowes

print version